Source: Eur Respir J 2015; 46: 1217-1221
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Milger Katrin, Kneidinger Nikolaus, Neurohr Claus, Reichenberger Frank, Behr Jürgen. Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF. Eur Respir J 2015; 46: 1217-1221

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and tolerability of nintedanib switched from pirfenidone for IPF patients Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 Premature discontinuation of patients: a potential bias in COPD clinical trials Source: Eur Respir J 2007; 30: 898-906 Year: 2007 Concomitant medications and efficacy of nintedanib in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events Source: Eur Respir J, 49 (5) 1602245; 10.1183/13993003.02245-2016 Year: 2017 Predictors of effects and adverse effects of pirfenidone on idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide Source: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005 Pleiotropic effects of add-on atorvastatin therapy during the treatment of COPD patients Source: Annual Congress 2011 - New treatments for airway disease Year: 2011 Anti-inflammatory effects of add-on atorvastatin therapy during the treatment of COPD patients Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Cardiovascular adverse effects during itraconazole therapy Source: Eur Respir J 2008; 32: 240 Year: 2008 Frequent adverse events during prolonged Bedaquiline treatment on XDR-tuberculosis patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Risk factors for discontinuation of roflumilast in COPD patients Source: International Congress 2017 – COPD management Year: 2017 Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease Source: Eur Respir J 2004; 24: Suppl. 48, 280s Year: 2004 Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 26 (146) 170057; 10.1183/16000617.0057-2017 Year: 2017 Effect of sildenafil add-on to antifibrotic treatment in IPF patients Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Patterns of discontinuation in patients with IPF treated with open-label nintedanib: data from INPULSIS-ON Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Adherence to inhaled controller therapy and local adverse events in children with asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Recent clinical treatment trials in IPF that focus on pirfenidone and nintedanib Source: International Congress 2014 – Ceremony for the ERS Idiopathic Pulmonary Fibrosis Research Award 2014 - Hot Topic: "Understanding and treating idiopathic pulmonary fibrosis (IPF) in the 21st century" Year: 2014